Market Overview

Amgen Announces Romosozumab Phase 2 Data Published In NEJM Show Significant Increases In Bone Mineral Density


Amgen (NASDAQ: AMGN) and UCB (OTC: UCBJF) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD). Published in the New England Journal of Medicine (NEJM), the trial demonstrated that, compared with placebo, romosozumab treatment for 12 months significantly increased BMD at the lumbar spine, total hip and femoral neck. Significant increases were also observed in the first BMD assessment at three months. Moreover, in exploratory analyses, increases observed at the lumbar spine and hip were significantly greater than those observed with current treatments FOSAMAX® (alendronate sodium) and FORTEO™/FORSTEO® (teriparatide).1   

See full press release


Related Articles (AMGN)

View Comments and Join the Discussion!

Posted-In: News Guidance Contracts Global